A consultative approach to service, delivery and problem solving ensured that a Polish pharmaceutical company received the equipment and technology it needed to ramp up production and expand into new geographies.
GEA has supplied one of the largest drug manufacturers in Korea with manufacturing equipment for a state-of-the-art pharma production plant. More than 7,000 VESTA® sterile valves were installed to direct the product flow in two identical insulin production lines. This was the first time VESTA® valve technology had been selected to completely equip a new greenfield project. The multimillion Euro order represents the biggest project so far in the history of the VESTA® line.
Caplin Group partners with GEA, a leading supplier of pharmaceutical containment equipment, to establish a state-of-the-art oncology plant in Chennai. Learn how Caplin's expansion plans and GEA's end-to-end solutions will enhance their production capabilities and deliver high-quality medicines.
Discover GEA's groundbreaking partnership with Oncogen Pharma in Malaysia, as they secure a multi-million Euro contract for the production of oral solid dosage (OSD) forms to treat cancer. Learn how GEA's end-to-end solutions and innovative technologies overcame challenges during the COVID-19 pandemic, ensuring successful project completion and customer satisfaction.
GEA’s first contained manufacturing line, including integrated granulation and tablet compression for the production of steroid/hormonal drugs, at STELLAPHARM in Vietnam is approaching completion
With the recent inclusion of a suite of fully automated, highly efficient production equipment to manufacture tablets and capsules, Pfizer’s plant in Freiburg, Germany, has been transformed into what the company calls a “Smart Factory.”
一个由制药企业和供应商组成的合作组织,包括辉瑞、GEA 和 G-CON Manufacturing,欢迎 GSK 加入联盟,该联盟致力于开发按需片剂生产所用的连续技术解决方案。
According to David Hobson, Sales Manager for Materials Handling Technology at GEA Pharma & Healthcare, it all started with a chance encounter at the ACHEMA 2012 trade show.
在进行广泛的市场调研后,Penn Pharma 发现剧毒药品外包研发和生产的固体剂型抗肿瘤药物市场需求有所增加。其生产场所的强效固体剂型产品制造历史已经超过 20 年,但仍需额外的产能。
为了研究连续生产 (CM) 并优化和加速药品开发过程,Pharmaceuticals, Inc. 联合 GEA 一起增强了现有的技术,并实现了主要的和备份的连续生产工艺。
当 GEA 向印度客户提供完整的抗肿瘤药物生产线时,他们不仅保证操作人员的健康和安全-符合国际公认标准-,公司也增加了产品收率、降低生产周期时间并实现了高度密闭方案。